JP2008500009A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500009A5
JP2008500009A5 JP2006532309A JP2006532309A JP2008500009A5 JP 2008500009 A5 JP2008500009 A5 JP 2008500009A5 JP 2006532309 A JP2006532309 A JP 2006532309A JP 2006532309 A JP2006532309 A JP 2006532309A JP 2008500009 A5 JP2008500009 A5 JP 2008500009A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006532309A
Other languages
Japanese (ja)
Other versions
JP2008500009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/006460 external-priority patent/WO2005051988A2/en
Publication of JP2008500009A publication Critical patent/JP2008500009A/ja
Publication of JP2008500009A5 publication Critical patent/JP2008500009A5/ja
Pending legal-status Critical Current

Links

JP2006532309A 2003-03-03 2004-03-02 全身性エリテマトーデスの治療のための組成物と方法 Pending JP2008500009A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45188403P 2003-03-03 2003-03-03
PCT/US2004/006460 WO2005051988A2 (en) 2003-03-03 2004-03-02 Compositions and methods for the treatment of systemic lupus erythematosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010089887A Division JP2010207229A (ja) 2003-03-03 2010-04-08 全身性エリテマトーデスの治療のための組成物と方法

Publications (2)

Publication Number Publication Date
JP2008500009A JP2008500009A (ja) 2008-01-10
JP2008500009A5 true JP2008500009A5 (enExample) 2009-05-14

Family

ID=34632721

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006532309A Pending JP2008500009A (ja) 2003-03-03 2004-03-02 全身性エリテマトーデスの治療のための組成物と方法
JP2010089887A Pending JP2010207229A (ja) 2003-03-03 2010-04-08 全身性エリテマトーデスの治療のための組成物と方法
JP2013121971A Pending JP2013240329A (ja) 2003-03-03 2013-06-10 全身性エリテマトーデスの治療のための組成物と方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010089887A Pending JP2010207229A (ja) 2003-03-03 2010-04-08 全身性エリテマトーデスの治療のための組成物と方法
JP2013121971A Pending JP2013240329A (ja) 2003-03-03 2013-06-10 全身性エリテマトーデスの治療のための組成物と方法

Country Status (6)

Country Link
US (2) US7749695B2 (enExample)
EP (1) EP1599498A2 (enExample)
JP (3) JP2008500009A (enExample)
AU (2) AU2004293369A1 (enExample)
CA (1) CA2518101A1 (enExample)
WO (1) WO2005051988A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790861B2 (en) * 1999-09-24 2010-09-07 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US7754435B2 (en) * 2000-09-21 2010-07-13 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
WO2007043103A1 (ja) * 2005-09-30 2007-04-19 Kansai Technology Licensing Organization Co., Ltd. シェーグレン症候群診断法及び診断キット
US20080057503A1 (en) 2006-04-24 2008-03-06 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
EP2369016A1 (en) * 2006-05-25 2011-09-28 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for diagnosing and treating graft rejection and inflammatory conditions
EP1905841A1 (en) * 2006-09-25 2008-04-02 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Trex1 as a marker for lupus erythematosus
WO2010011965A2 (en) * 2008-07-24 2010-01-28 The Regents Of The University Of California Identifying high risk clinically isolated syndrome patients
HUE032917T2 (hu) * 2009-09-03 2017-11-28 Medimmune Llc 1-es típusú interferon diagnosztikum
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
PT2831109T (pt) 2012-03-28 2018-02-07 Gadeta B V Resumo
CA3026180A1 (en) 2016-06-10 2017-12-14 Gadeta B.V. Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
EP3541407A1 (en) * 2016-11-18 2019-09-25 Universitat de Barcelona Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US20230210942A1 (en) * 2018-01-09 2023-07-06 Imagine Pharma Llc Methods and compositions for modulating endothelial cell dysfunction
GB202012804D0 (en) * 2020-08-17 2020-09-30 Univ London Queen Mary Agrin polypeptide and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016660A1 (en) * 1991-03-22 1992-10-01 Sloan-Kettering Institute For Cancer Research Methods for detection and treatment of cancer
CA2343006A1 (en) * 1998-09-17 2000-03-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2362427A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1171457A1 (en) * 1999-03-19 2002-01-16 Human Genome Sciences, Inc. 46 human secreted proteins
EP1234036A2 (en) * 1999-11-30 2002-08-28 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ATE444361T1 (de) * 1999-12-23 2009-10-15 Genentech Inc Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2003529774A (ja) 2000-03-31 2003-10-07 ジェネンテック・インコーポレーテッド 遺伝子発現を検出し定量するための構成物及び方法
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20040110668A1 (en) * 2000-10-02 2004-06-10 Burgess Christopher C. Nucleic acid sequences differentially expressed in cancer tissue
US20020137081A1 (en) * 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
WO2002057454A2 (en) 2001-01-19 2002-07-25 Incyte Genomics, Inc. Receptors and membrane-associated proteins
WO2003010327A2 (en) * 2001-02-21 2003-02-06 Curagen Corporation Novel proteins and nucleic acids encoding same
EP1478772A2 (en) * 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US6489153B1 (en) * 2001-10-31 2002-12-03 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
JP2005535290A (ja) * 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
US7118865B2 (en) * 2002-08-16 2006-10-10 Regents Of The University Of Minnesota Methods for diagnosing severe systemic lupus erythematosus
EP1578373A4 (en) * 2002-09-11 2007-10-24 Genentech Inc NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
EP2500438A3 (en) * 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
EP1578368A4 (en) * 2002-11-12 2008-01-23 Genentech Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
WO2004047728A2 (en) * 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus

Similar Documents

Publication Publication Date Title
BE2024C508I2 (enExample)
BE2023C542I2 (enExample)
BE2022C549I2 (enExample)
BE2021C001I2 (enExample)
BE2020C513I2 (enExample)
BE2020C517I2 (enExample)
FR19C1052I1 (enExample)
BE2019C548I2 (enExample)
BE2019C506I2 (enExample)
BE2018C045I2 (enExample)
BE2020C525I2 (enExample)
BE2017C063I2 (enExample)
BE2015C038I2 (enExample)
BE2015C014I2 (enExample)
BE2014C071I2 (enExample)
BE2015C015I2 (enExample)
BE2014C064I2 (enExample)
BE2014C063I2 (enExample)
BE2014C010I2 (enExample)
BE2014C014I2 (enExample)
BE2013C071I2 (enExample)
BE2013C021I2 (enExample)
JP2005046158A5 (enExample)
JP2005084049A5 (enExample)
BE2015C033I2 (enExample)